ReviewDrugs in context2019
Menopause hormone therapy: latest developments and clinical practice.
Review in Drugs in context, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 142 citations in OpenAlex.
- A prospective, randomized, double-blind, placebo-controlled study on efficacy and safety of Ashwagandha root extract (Frontiers in reproductive health · 2025Trial
- Trial
- The effect of estradiol and selective estrogen receptor modulators on lipid profile in the ovariectomized rat model.Research in pharmaceutical sciences · 2026Article
- Effect ofJournal of microbiology and biotechnology · 2026Article
- Menopausal hormone therapy and risk of neuropsychiatric disease: a drug target Mendelian randomisation study.npj women's health · 2026Article
- Smooth muscle of the lower urinary tract: BK-RyR coupling in physiology and pathophysiology.Journal of muscle research and cell motility · 2025Review
- QbD-Driven preparation, characterization, and pharmacokinetic investigation of daidzein-l oaded nano-cargos of hydroxyapatite.Scientific reports · 2025Article
- Operationalizing the Women-Centred HIV Care Model for trans women and persons with transfeminine experience living with and affected by HIV: A qualitative study.International journal of transgender health · 2025Article
- Exploring the innovative application of cerium oxide nanoparticles for addressing oxidative stress in ovarian tissue regeneration.Journal of ovarian research · 2024Review
- Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause.Nature aging · 2024Review
- Article
- Pharmacotherapeutic Considerations on Telomere Biology: The Positive Effect of Pharmacologically Active Substances on Telomere Length.International journal of molecular sciences · 2024Review
- Inflammation as a Potential Mechanism Contributing to Sexual Functioning Following Initiation of Gender-Affirming Hormone Therapy.Current sexual health reports · 2024Article
- Global Natural Products Social (GNPS)-Based Molecular-Networking-Guided Isolation of Phenolic Compounds fromPlants (Basel, Switzerland) · 2023Article
- A cross-sectional study of symptoms and health-related quality of life in menopausal-aged women in China.BMC women's health · 2023Article
- Efficiency and safety of acupuncture for women with premature ovarian insufficiency: study protocol for a randomized controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Article
- Effectiveness of Tibolone in Relieving Postmenopausal Symptoms for a Short-Term Period in Indian Women.Journal of obstetrics and gynaecology of India · 2023Article
- Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.ACS infectious diseases · 2023Article
- Hormone Replacement Therapy Does Not Eliminate Risk Factors for Joint Complications following Total Joint Arthroplasty: A Matched Cohort Study.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023Article
- Supraphysiologic Vaginal Estrogen Therapy in Aged Mice Mitigates Age-Associated Bladder Inflammatory Response to Urinary Tract Infections.Urogynecology (Philadelphia, Pa.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.